ERA Congress 2024
ERA Congress 2024
Advertisement
Anjay Rastogi, MD, PhDERA Congress 2024 | June 13, 2025
Anjay Rastogi, MD, PhD, spoke about findings from the ZORA study regarding the efficacy of SZC for hyperkalemia.
Fadi Fakhouri, MD, PhDERA Congress 2024 | June 13, 2025
Nephrology Times spoke with Fadi Fakhouri, MD, PhD, about results from the NOBLE trial of pegcetacoplan for C3G and ICMPGN.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Iptacopan with supportive care resulted in a notable reduction in proteinuria in patients with C3 glomerulopathy.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Atrasentan showed a statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN).
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Semaglutide helped stem kidney function decline in patients with cardiovascular disease plus overweight or obesity.
Charlotte RobinsonERA Congress 2024 | June 6, 2024
Antinephrin autoantibodies can be a biomarker for the progression of kidney diseases associated with nephrotic syndrome.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
FLOW trial results showed that semaglutide has significant benefits for kidney disease events, CV outcomes, and mortality.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
A team developed a machine learning classifier for 12 classes of glomerulonephritis.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
A study compared hospitalization and survival rates of patients receiving twice-weekly versus thrice-weekly hemodialysis.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Researchers developed a method to score predictors of relapse in patients with ANCA-associated vasculitis having CYC therapy.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
A study found that renal progenitor cells may serve as an early biomarker for renal injury in Fabry disease.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Researchers reported on efficacy of a personalized treatment protocol for membranous nephropathy versus a rituximab protocol.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
A research team examined the potential benefit of targeting claudin-1 (CLDN1) in crescentic glomerulonephritis (CrGN).
Charlotte RobinsonERA Congress 2024 | June 13, 2025
KDIGO classifications for the burden and impact of renal and CV adverse outcomes in type 1 diabetes are underutilized.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Researchers shared interim results from the ORIGIN study of atacicept in patients with IgA nephropathy.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Even with treatment, many patients do not fully recover kidney function after drug-induced acute interstitial nephritis.
Charlotte RobinsonERA Congress 2024 | June 13, 2025
Researchers examined the eligibility of patients with CKD for five cardiovascular RCTs and the reasons for ineligibility.
Advertisement